

<b>Nerve Agent / Organophosphate Poisoning</b>	
The incident commander is in charge of the scene and you are to follow his/her direction for entering and exiting the scene. Patients in the hot and warm zones <b>MUST</b> be decontaminated prior to entering the cold zone.	
<b>ADULT</b>	<b>PEDIATRIC</b>
<b>BLS Procedures</b>	
<p><i>Patients that are exhibiting obvious signs of exposure (SLUDGEM) of organophosphate exposure and/or nerve agents</i></p> <p>Maintain airway and position of comfort</p> <p>Administer oxygen as indicated</p> <ul style="list-style-type: none"> <li>• <b>Mark I or DuoDote Antidote Kit</b> <ul style="list-style-type: none"> <li>○ Mild Exposure: IM x 1</li> <li>○ Moderate Exposure: IM x1                             <ul style="list-style-type: none"> <li>• May repeat in 10 minutes if symptoms persist</li> </ul> </li> <li>○ Severe Exposure: IM x 3 in rapid succession, rotating injection sites</li> </ul> </li> </ul>	
<b>ALS Standing Orders</b>	
<p><i>Patients that are exhibiting obvious signs of exposure (SLUDGEM) of Organophosphate exposure and/or Nerve Agents</i> <i>If not already administered by BLS personnel:</i></p> <ul style="list-style-type: none"> <li>• <b>Mark I or DuoDote Antidote Kit</b> <ul style="list-style-type: none"> <li>○ Mild Exposure: IM x 1</li> <li>○ Moderate Exposure: IM x1                             <ul style="list-style-type: none"> <li>• May repeat in 10 minutes if symptoms persist</li> </ul> </li> <li>○ Severe Exposure: IM x 3 in rapid succession, rotating injection sites</li> </ul> </li> </ul> <p><u>For seizures:</u></p> <ul style="list-style-type: none"> <li>• Midazolam                             <ul style="list-style-type: none"> <li>○ IV/IO – 2 mg                                     <ul style="list-style-type: none"> <li>• Repeat 1 mg q 2 min as needed</li> <li>• Max 5 mg</li> </ul> </li> <li>○ IM – 0.1 mg/kg                                     <ul style="list-style-type: none"> <li>• Max 5 mg</li> </ul> </li> </ul> </li> </ul>	<p><i>Patients that are exhibiting obvious signs of exposure (SLUDGEM) of Organophosphate exposure and/or Nerve Agents</i> <i>If not already administered by BLS personnel:</i></p> <ul style="list-style-type: none"> <li>• <b>Mark I or DuoDote Antidote Kit</b> <ul style="list-style-type: none"> <li>○ Mild Exposure: IM x 1</li> <li>○ Moderate Exposure: IM x1                             <ul style="list-style-type: none"> <li>• May repeat in 10 minutes if symptoms persist</li> </ul> </li> <li>○ Severe Exposure: IM x 3 in rapid succession, rotating injection sites</li> </ul> </li> </ul> <p><u>For seizures:</u></p> <ul style="list-style-type: none"> <li>• Midazolam                             <ul style="list-style-type: none"> <li>○ IM – 0.1 mg/kg                                     <ul style="list-style-type: none"> <li>• Max 5 mg</li> </ul> </li> </ul> </li> </ul>
<b>Base Hospital Orders Only</b>	
Consult with ED Physician for further treatment measures	
<ul style="list-style-type: none"> <li>• Refer to VCEMS Policy 705.18-Overdose/Poisoning for organophosphate poisoning treatment guidelines.</li> <li>• DuoDote contains 2.1 mg Atropine Sulfate and 600 mg Pralidoxime Chloride.</li> <li>• <b>Diazepam</b> is available in the CHEMPACK and may be deployed in the event of a nerve agent exposure. Paramedics may administer diazepam using the following dosages for the treatment of seizures:                             <ul style="list-style-type: none"> <li>○ <b>Adult:</b> 5 mg IM/IV/IO q 10 min titrated to effect (<i>max 30 mg</i>)</li> <li>○ <b>Pediatric:</b> 0.1 mg/kg IV/IM/IO (max initial dose 5 mg) over 2-3 min q 10 min titrated to effect (<i>max total dose 10 mg</i>)</li> </ul> </li> <li>• Mild exposure with symptoms:                             <ul style="list-style-type: none"> <li>○ Miosis, rhinorrhea, drooling, sweating, blurred vision, nausea, bradypnea or tachypnea, nervousness, fatigue, minor memory disturbances, irritability, unexplained tearing, wheezing, tachycardia, bradycardia</li> </ul> </li> <li>• Moderate exposure with symptoms:                             <ul style="list-style-type: none"> <li>○ Miosis, rhinorrhea, SOB, wheezing, secretions, soft muscle weakness and fasciculations, GI effects</li> </ul> </li> <li>• Severe exposure with symptoms:                             <ul style="list-style-type: none"> <li>○ Strange confused behavior, severe difficulty breathing, twitching, unconsciousness, seizing, flaccid, apnea pinpoint pupils involuntary defecation, urination</li> </ul> </li> </ul>	

Effective Date: June 1, 2018  
Next Review Date: April 30, 2020

Date Revised: April 12, 2018  
Last Reviewed: April 12, 2018

  
VCEMS Medical Director